Figure 2. CONSORT diagram of the CICARO trial.

Patients were screened in weekly interdisciplinary tumor board meetings and eligibility criteria checked. Eligible patients were contacted by phone regarding possible study participation and, if interested, scheduled for a baseline visit V1, where written informed consent was obtained prior to study inclusion and procedures. Follow-up study visit V2 was scheduled at least 2 weeks after the last chemotherapy application or approximately 6 months after V1 for control patients. A total of n = 10 patients were lost to follow-up (i.e., could not be reached, withdrawal of consent, death) and were excluded from the final analysis.